Results 131 to 140 of about 2,233 (157)

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison

Journal of Medical Economics, 2022
Andrew Menzies-Gow, Pallavi B Rane, Jennifer Rowell   +2 more
exaly  

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Journal of Clinical Pharmacology, 2021
Janet Griffiths, Neang S. Ly, Yanan Zheng   +2 more
exaly  

Is tezepelumab the ubiquitous biologic for severe asthma?

The Lancet Respiratory Medicine, 2023
Beasley, Richard, Chang, Anne B.
openaire   +4 more sources

Tezepelumab in the Treatment of Uncontrolled Severe Asthma

Annals of Pharmacotherapy, 2023
Pramodini B Kale-Pradhan, Melissa Lipari
exaly  

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men

Clinical Pharmacology in Drug Development, 2020
Nobuya Hayashi, Song Ren, Shunji Matsuki
exaly  

Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis

Current Allergy and Asthma Reports, 2023
Gabriel Cavalcante Lima Chagas
exaly  

Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab

The Journal of Allergy and Clinical Immunology: In Practice, 2023
openaire   +2 more sources

Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study

Clinical and Experimental Allergy, 2023
Jonathan Corren, Janet Griffiths, Jean-Pierre Llanos   +2 more
exaly  

Tezepelumab in active osteoarthritis with asthma

Journal of Allergy and Clinical Immunology
Roberto Colli, Jakob Nilsson, Lukas Frischknecht   +2 more
openaire   +2 more sources

NAVIGATOR steers asthma patients to tezepelumab

Medicom Conference Report ATS 2022, 2022
Njira Lugogo, Rachel Giles
openaire   +1 more source